Table 2. Ongoing clinical trials of relapsed small-cell lung cancer.
| Trial number | Phase | Treatment | Primary endpoint |
|---|---|---|---|
| Antiangiogenic agent | |||
| NCT03651219 | III | Irinotecan + apatinib | Duration of treatment |
| Irinotecan | |||
| NCT03823118 | II | S1 + anlotinib | ORR, PFS |
| NCT03732846 | II | Anlotinib | PFS |
| PARP inhibitor | |||
| NCT03009682 (SUKSES-B) | II | Olaparib | ORR |
| NCT03428607 (SUKSES-N2) | II | Azd6738 + olaparib | ORR |
| NCT02769962 | I/II | Crlx101 + olaparib | ORR, MTD, RP2D |
| NCT03672773 | II | Talazoparib + temozolomide | ORR |
| NCT02734004 (MEDIOLA) | I/II | Olaparib + MEDI4736 | DCR, safety, etc. |
| Olaparib + MEDI4736 + bevacizumab | |||
| NCT02498613 | II | Olaparib + cediranib | ORR |
| Immunocheckpoint inhibitor | |||
| NCT02701400 | II | Durvalumab + tremelimumab + RT | PFS, ORR |
| Durvalumab + tremelimumab | |||
| NCT02247349 | I/II | BMS-986012 ± nivolumab | Safety |
| NCT03728361 | II | Nivolumab + temozolomide | ORR |
| NCT04173325 | I | Nivolumab + irinotecan | Frequently & severity AE |
| NCT03554473 | I/II | M7824 | Efficacy |
| M7824 + topotecan | |||
| M7824 + temozolomide | |||
| NCT03994744 | II | Sintilimab + metformin | ORR, safety |
| NCT04056949 | II | (Nab-)Paclitaxel + sintilimab | PFS |
| NCT03639194 | I | ABBV-011 ± ABBV-181 | MTD, RPTD |
| Cytotoxic drug | |||
| NCT02566993 (ATLANTIS) | III | Lurbinectedin + doxorubicin | OS |
| Cyclophosphamide + doxorubicin + vincristine | |||
| NCT03613753 | II | Irinotecan + lobaplatin | ORR |
| Irinotecan | |||
| NCT01876446 | II | Pegylated irinotecan | 18-week PFS rate |
| NCT02769832 | II | Nab-paclitaxel + gemcitabine | RR |
| Other | |||
| NCT03061812 (TAHOE) | III | Rovalpituzumab tesirine | OS |
| Topotecan | |||
| NCT03098030 (IV-SCLC-301) | II/III | Irinotecan + dinutuximab | OS |
| Irinotecan | |||
| Topotecan | |||
| NCT02593019 | II | AZD1775 | ORR |
| NCT03896503 | II | Topotecan + M6620 | PFS |
| Topotecan | |||
| NCT04210037 | I/II | Paclitaxel + APG-1252 | DLT, MTD |
| NCT02649673 | I/II | Topotecan + LCL161 | DLT |
| NCT03366103 | I/II | Navitoclax + vistusertib | Adverse events, ORR |
| NCT03460977 | I | PF-06821497 | DLT, safety |
ORR, objective response rate; PFS, progression-free survival; MTD, maximum tolerated dose; RP2D/RPTD, recommended phase II dose; DCR, disease control rate; AE, adverse events; OS, overall survival; RR, response rate; DLT, dose-limiting toxicity.